Elicio Therapeutics grants director 21,750 options

A non-employee director of Elicio Therapeutics received a new annual stock option grant vesting in 2027.

Rhea-AI Filing Summary

Elicio Therapeutics, Inc. (ELTX) reported that director Carol Gail Ashe received a grant of stock options for 21,750 shares of common stock on August 31, 2026. The options have an exercise price of $2.70 per share and expire on August 31, 2036. They represent the annual non-employee director equity award and will vest in full on the earlier of August 31, 2027 or the 2027 annual stockholders meeting, subject to continued service.

Insider Trade Summary

Grant/Award: 21,750 shares

Grant/Award 1 txn

Insider Ashe Carol Gail

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	21,750	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 21,750 contracts (Direct)

Footnotes (1)

1. F1. The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders.

Key Figures

Stock options granted: 21,750 options Exercise price: $2.70 per share Expiration date: August 31, 2036 +2 more

5 metrics

Stock options granted 21,750 options Annual non-employee director equity award granted on August 31, 2026

Exercise price $2.70 per share Exercise price of the stock options for Elicio Therapeutics common stock

Expiration date August 31, 2036 Expiration of the granted stock options

Shares underlying options 21,750 shares Each option is exercisable for one share of common stock

Vesting date reference August 31, 2027 or 2027 annual meeting Options vest on the earlier of these dates, subject to continued service

Key Terms

stock option, exercise price, vest and become exercisable, non-employee director equity award

4 terms

stock option financial

"The stock option represents the annual non-employee director equity award"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"have an exercise price of $2.70 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest and become exercisable financial

"shall vest and become exercisable in full on the earlier of"

non-employee director equity award financial

"represents the annual non-employee director equity award"

FAQ

What equity award did Elicio Therapeutics (ELTX) grant to director Carol Gail Ashe?

Elicio Therapeutics granted Carol Gail Ashe stock options for 21,750 shares of common stock as her annual non-employee director equity award, with an exercise price of $2.70 per share and expiration on August 31, 2036.

When do the new ELTX stock options granted to the director vest?

The options vest and become exercisable in full on the earlier of August 31, 2027, the one-year anniversary of grant, or the 2027 annual stockholders meeting, subject to the director continuing to provide services through the vesting date.

How many ELTX options does the director hold after this Form 4 transaction?

After this transaction, the director is reported as holding 21,750 stock options directly, each exercisable for one share of Elicio Therapeutics common stock, reflecting the full amount of this annual grant.

What is the exercise price of the ELTX options granted to the director?

The granted stock options have an exercise price of $2.70 per share of Elicio Therapeutics common stock, as reported in the Form 4 derivative transaction details.

Will the director receive another equity award at the 2026 ELTX annual meeting?

No. The filing states that no additional equity award will be made to the director in connection with the 2026 annual meeting of stockholders, as this grant represents the annual non-employee director award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:05 PM Accepted by SEC EDGAR 09/02/2026 - 04:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ashe Carol Gail

(Last) (First) (Middle)

C/O ELICIO THERAPEUTICS, INC.

451 D STREET, 5TH FLOOR, SUITE 501

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Elicio Therapeutics, Inc. [ ELTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.7	08/31/2026		A		21,750		(1)	08/31/2036	Common Stock	21,750	$0	21,750	D

Explanation of Responses:

1. The stock option represents the annual non-employee director equity award to the Reporting Person and shall vest and become exercisable in full on the earlier of (A) August 31, 2027, the one-year anniversary of the date of grant, and (B) the annual meeting of the Issuer's stockholders held in 2027, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date. No additional equity award will be made to the Reporting Person in connection with the 2026 annual meeting of stockholders.

Remarks:

	/s/ Carol Ashe	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)